FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinically meaningful” benefit. AstraZeneca touted ...
April 30, 2026 02:56 PM EDT R&DFDA+ FDA's oncology advisors vote against 'new paradigm' in AstraZeneca breast cancer trial Nicole DeFeudis Senior Reporter In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that